Ticagrelor (Brilinta)

General information

Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y₁₂ class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a

History of changes in FDA indication

Note that this agent does not have a hematology-specific indication at this time.

• 7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
• 9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI).